Osimertinib Improves the Immune Microenvironment of Lung Cancer by Downregulating PD-L1 Expression of Vascular Endothelial Cells and Enhances the Antitumor Effect of Bevacizumab

OBJECTIVE: To investigate the effect and mechanism of osimertinib combined with bevacizumab on lung cancer through cell and transplanted tumor animal experiments and to provide theoretical basis for further clinical trials. METHODS: Immunohistochemistry was used to detect the expression of PD-L1 in...

Descripción completa

Detalles Bibliográficos
Autores principales: Xiao, Xuejun, Wu, Yang, Shen, Fang, MuLaTiAize, Yusufu, Xinhua, Nabi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9246595/
https://www.ncbi.nlm.nih.gov/pubmed/35783156
http://dx.doi.org/10.1155/2022/1531353

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9246595/
https://www.ncbi.nlm.nih.gov/pubmed/35783156
http://dx.doi.org/10.1155/2022/1531353

Ejemplares similares